The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,150.00
Bid: 12,146.00
Ask: 12,150.00
Change: -96.00 (-0.78%)
Spread: 4.00 (0.033%)
Open: 12,240.00
High: 12,306.00
Low: 12,132.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-S.Africa targets COVID-19 vaccines next month but deals not yet signed

Sun, 03rd Jan 2021 17:52

* S.Africa battling COVID-19 resurgence

* Experts criticise govt's vaccine strategy

* Ministry still in talks with pharma companies over deals

* Vaccines from COVAX scheme only expected in Q2
(Adds detail on govt rollout plan)

By Alexander Winning

JOHANNESBURG, Jan 3 (Reuters) - South Africa aims to get
COVID-19 vaccines by next month but is still in talks with
pharmaceutical companies and no deals have been signed yet,
Health Minister Zweli Mkhize said on Sunday, amid growing
criticism of the government's response.

The country is battling a resurgence in coronavirus
infections driven partly by a new variant called 501.V2. It has
recorded more than 1 million infections, the most on the African
continent, and more than 29,000 deaths.

In an opinion piece published in major local news outlets on
Saturday, a group of prominent health experts criticised the
government for moving too slowly to procure sufficient vaccines.

Africa's most industrialised nation is participating in the
COVAX vaccine distribution initiative co-led by the World Health
Organization but the scheme could only cover 10% of its
population of roughly 60 million people and the first doses may
only arrive in the second quarter of the year.

That has caused anxiety among some scientists and academics,
who have urged the government to reach agreements with
pharmaceutical companies quickly given that other countries have
already started vaccinating.

Mkhize said at a news conference that officials were doing
everything possible to obtain vaccines before the COVAX doses
become available.

"We are targeting February, although all of that will depend
very much on the success of the current bilateral negotiations,"
he said.

Mkhize said the ultimate aim was to vaccinate a minimum of
67% of the population to reach herd immunity.

He said the approach would be to target frontline healthcare
workers in the first phase of vaccination, followed by a second
phase comprising essential workers, people in congregate
settings, people over the age of 60 and those aged over 18 with
co-morbidities. A third phase of the rollout would target other
people over the age of 18.

The government has had discussions with vaccine
manufacturers including Pfizer, Moderna,
AstraZeneca and Johnson & Johnson, as well as
with ones in Russia and China, a health ministry presentation
showed.

The presentation said negotiations had progressed well and
the government was fairly confident of having supply in the
first quarter.

Mkhize said officials were considering three mechanisms to
fund vaccine procurement: government financing, medical aids and
a private sector contribution.

New daily cases hit a record 18,000 several days ago but
have dipped slightly since.
(Reporting by Alexander Winning, Editing by Timothy Heritage
and Alexandra Hudson)

More News
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.